Skip to main
CRBP
CRBP logo

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. is making significant advancements in its oncology pipeline, marked by an increased patient enrollment and promising preclinical evidence, particularly for CRB-601, which targets TGF activation in cancer cells. The recent data presented at ASCO GU 2025 highlights CRB-701's favorable risk-benefit profile and an overall response rate of approximately 44%, surpassing that of competitive therapies, indicating its potential for superior safety and efficacy. Collectively, these developments support a strong outlook for the company's stock, emphasizing the innovative nature of its product offerings and their potential to address critical unmet medical needs in the oncology space.

Bears say

Corbus Pharmaceuticals is currently facing a negative outlook due to its valuation being perceived as an overreaction to competitive data, particularly from Novo Nordisk's obesity treatment announcements, which may lead to adverse comparisons with its candidate CRB-913. The potential non-achievement of regulatory approvals or delays in the approval timelines for its product pipeline, including CRB-701 and CRB-601, could substantially harm the company's share price. Additionally, concerns regarding safety profiles—particularly related to ocular toxicity in its therapeutic candidate Tivdak—may hinder adoption and, subsequently, revenue generation for the company.

CRBP has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 13 analysts, CRBP has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.